Gefitinib for EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients

NCT02526537 · clinicaltrials.gov ↗
TERMINATED
Status
10
Enrollment
OTHER
Sponsor class

Stopped Similar study has revealed result of no benefit for participants

Conditions

Sponsor

Lunxu Liu